New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia
[adsense:336x280:8701650588]
Only 1 in 3 (36%) of people have heard of Acute Myeloid Leukaemia (AML), reveals survey of 2,520 people from across Europe.
Awareness varied between the 5 countries surveyed: Italy demonstrated the highest awareness of AML (53%) and France the lowest (24%).
An overwhelming majority (67%)4 believed leukaemia to be a ‘treatable’ form of cancer. However in the case of AML, prognosis is considered poor and worsens with age1 and40% of AML patients are ineligible for the current standard of care (intensive chemotherapy) due to age and co-morbidities.
[adsense:468x15:2204050025]
Erin Schwartz, VP of Strategic Partnerships and Global Advocacy at the MAX Foundation comments, “People often believe that treatment of blood cancers is very straight forward these days, but this is not the case. For Acute Myeloid Leukaemia (AML) prognosis remains poor, particularly for older patients who cannot tolerate intensive chemotherapy and who have limited treatment options. It is important that we educate people about AML and raise awareness of the support services available to patients and families affected by the disease.”